{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:59:30Z","timestamp":1770512370163,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["20001234"],"award-info":[{"award-number":["20001234"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI19C0218"],"award-info":[{"award-number":["HI19C0218"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI16C0992"],"award-info":[{"award-number":["HI16C0992"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["1F31LM012636-01"],"award-info":[{"award-number":["1F31LM012636-01"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006063","name":"Paul and Daisy Soros Fellowships for New Americans","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01 GM101430"],"award-info":[{"award-number":["R01 GM101430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01 GM101430"],"award-info":[{"award-number":["R01 GM101430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alendronate and raloxifene are among the most popular anti-osteoporosis medications. However, there is a lack of head-to-head comparative effectiveness studies comparing the two treatments. We conducted a retrospective large-scale multicenter study encompassing over 300 million patients across nine databases encoded in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The primary outcome was the incidence of osteoporotic hip fracture, while secondary outcomes were vertebral fracture, atypical femoral fracture (AFF), osteonecrosis of the jaw (ONJ), and esophageal cancer. We used propensity score trimming and stratification based on an expansive propensity score model with all pre-treatment patient characteritistcs. We accounted for unmeasured confounding using negative control outcomes to estimate and adjust for residual systematic bias in each data source. We identified 283,586 alendronate patients and 40,463 raloxifene patients. There were 7.48 hip fracture, 8.18 vertebral fracture, 1.14 AFF, 0.21 esophageal cancer and 0.09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0.69, 0.22 and 0.06 events per 1,000 person-years, respectively, in the raloxifene cohort. Alendronate and raloxifene have a similar hip fracture risk (hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.94\u20131.13), but alendronate users are more likely to have vertebral fractures (HR 1.07, 95% CI 1.01\u20131.14). Alendronate has higher risk for AFF (HR 1.51, 95% CI 1.23\u20131.84) but similar risk for esophageal cancer (HR 0.95, 95% CI 0.53\u20131.70), and ONJ (HR 1.62, 95% CI 0.78\u20133.34). We demonstrated substantial control of measured confounding by propensity score adjustment, and minimal residual systematic bias through negative control experiments, lending credibility to our effect estimates. Raloxifene is as effective as alendronate and may remain an option in the prevention of osteoporotic fracture.<\/jats:p>","DOI":"10.1038\/s41598-020-68037-8","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T10:03:14Z","timestamp":1594029794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis"],"prefix":"10.1038","volume":"10","author":[{"given":"Yeesuk","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vojtech","family":"Huser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe G.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hojun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mui","family":"Van Zandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Vashisht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Duke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hripcsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigam H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn J.","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Suchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"68037_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone, H. G. et al. Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa030897 (2004).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4055\/cios.2018.10.2.149","volume":"10","author":"B Nguyen","year":"2018","unstructured":"Nguyen, B., Hoshino, H., Togawa, D. & Matsuyama, Y. Cortical thickness index of the proximal femur: A radiographic parameter for preliminary assessment of bone mineral density and osteoporosis status in the age 50 years and over population. Clin. Orthop. Surg. 10, 149\u201356. https:\/\/doi.org\/10.4055\/cios.2018.10.2.149 (2018).","journal-title":"Clin. Orthop. Surg."},{"key":"68037_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6874-13-15","volume":"13","author":"SA Foster","year":"2013","unstructured":"Foster, S. A. et al. Fractures in women treated with raloxifene or alendronate: A retrospective database analysis. BMC Womens Health 13, 15. https:\/\/doi.org\/10.1186\/1472-6874-13-15 (2013).","journal-title":"BMC Womens Health"},{"key":"68037_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund, E. et al. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteop. 8, 136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1 (2013).","journal-title":"Arch Osteop."},{"key":"68037_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3349\/ymj.2014.55.4.1049","volume":"55","author":"EJ Park","year":"2014","unstructured":"Park, E. J. et al. Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008\u20132011. Yonsei Med. J. 55, 1049\u201357. https:\/\/doi.org\/10.3349\/ymj.2014.55.4.1049 (2014).","journal-title":"Yonsei Med. J."},{"key":"68037_CR6","doi-asserted-by":"publisher","first-page":"796510","DOI":"10.1155\/2014\/796510","volume":"2014","author":"T Lin","year":"2014","unstructured":"Lin, T. et al. Alendronate versus raloxifene for postmenopausal women: A meta-analysis of seven head-to-head randomized controlled trials. Int. J. Endocrinol. 2014, 796510. https:\/\/doi.org\/10.1155\/2014\/796510 (2014).","journal-title":"Int. J. Endocrinol."},{"key":"68037_CR7","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00198-010-1208-3","volume":"21","author":"PD Miller","year":"2010","unstructured":"Miller, P. D. & Derman, R. J. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteop. Int. 21, 1793\u2013802. https:\/\/doi.org\/10.1007\/s00198-010-1208-3 (2010).","journal-title":"Osteop. Int."},{"key":"68037_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black, D. M. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med 362, 1761\u201371. https:\/\/doi.org\/10.1056\/NEJMoa1001086 (2010).","journal-title":"N. Engl. J. Med"},{"key":"68037_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (more) investigators. JAMA 282, 637\u201345 (1999).","journal-title":"JAMA"},{"key":"68037_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/0003-4819-148-9-200805060-00003","volume":"148","author":"SM Cadarette","year":"2008","unstructured":"Cadarette, S. M. et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann. Intern. Med. 148, 637\u201346 (2008).","journal-title":"Ann. Intern. Med."},{"key":"68037_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00774-016-0809-0","volume":"36","author":"S Tanaka","year":"2018","unstructured":"Tanaka, S., Yamamoto, T., Oda, E., Nakamura, M. & Fujiwara, S. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: Retrospective analysis of a hospital claims database. J. Bone Miner. Metab. 36, 87\u201394. https:\/\/doi.org\/10.1007\/s00774-016-0809-0 (2018).","journal-title":"J. Bone Miner. Metab."},{"key":"68037_CR12","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak, G. et al. Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 216, 574\u20138 (2015).","journal-title":"Stud. Health Technol. Inform."},{"key":"68037_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/sim.5925","volume":"33","author":"MJ Schuemie","year":"2014","unstructured":"Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A. & Madigan, D. Interpreting observational studies: Why empirical calibration is needed to correct p-values. Stat. Med. 33, 209\u201318. https:\/\/doi.org\/10.1002\/sim.5925 (2014).","journal-title":"Stat. Med."},{"issue":"Suppl 1","key":"68037_CR14","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1007\/s40264-013-0099-6","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan, P. B., Schuemie, M. J., Gruber, S., Zorych, I. & Madigan, D. Empirical performance of a new user cohort method: Lessons for developing a risk identification and analysis system. Drug Saf. 36(Suppl 1), S59-72. https:\/\/doi.org\/10.1007\/s40264-013-0099-6 (2013).","journal-title":"Drug Saf."},{"key":"68037_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","volume":"19","author":"JM Overhage","year":"2012","unstructured":"Overhage, J. M., Ryan, P. B., Reich, C. G., Hartzema, A. G. & Stang, P. E. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 19, 54\u201360. https:\/\/doi.org\/10.1136\/amiajnl-2011-000376 (2012).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"68037_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.4338\/ACI-2014-12-CR-0121","volume":"6","author":"F FitzHenry","year":"2015","unstructured":"FitzHenry, F. et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl. Clin. Inform. 6, 536\u2013547 (2015).","journal-title":"Appl. Clin. Inform."},{"key":"68037_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard, M. A. et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet 394, 1816\u20131826 (2019).","journal-title":"Lancet"},{"key":"68037_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0962280211403601","volume":"22","author":"P Ryan","year":"2013","unstructured":"Ryan, P. Statistical challenges in systematic evidence generation through analysis of observational healthcare data networks. Stat. Methods Med. Res. 22, 3\u20136. https:\/\/doi.org\/10.1177\/0962280211403601 (2013).","journal-title":"Stat. Methods Med. Res."},{"key":"68037_CR19","unstructured":"Schuemie, M.\u00a0J., Suchard, M.\u00a0A. & Ryan, P.\u00a0B. Cohortmethod: New-user cohort method with large scale propensity and outcome models. https:\/\/github.com\/OHDSI\/CohortMethod (2015). Accessed 21 June 2020."},{"key":"68037_CR20","doi-asserted-by":"publisher","DOI":"10.1145\/2414416.2414791","author":"MA Suchard","year":"2013","unstructured":"Suchard, M. A., Simpson, S. E., Zorych, I., Ryan, P. & Madigan, D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans. Model Comput. Simul.\nhttps:\/\/doi.org\/10.1145\/2414416.2414791 (2013).","journal-title":"ACM Trans. Model Comput. Simul."},{"key":"68037_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score inobservational studies for causal effects. Biometrika 70, 41\u201355 (1983).","journal-title":"Biometrika"},{"key":"68037_CR22","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ije\/dyy120","volume":"47","author":"Y Tian","year":"2018","unstructured":"Tian, Y., Schuemie, M. J. & Suchard, M. A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int. J. Epidemiol. 47, 2005\u20132014. https:\/\/doi.org\/10.1093\/ije\/dyy120 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"68037_CR23","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","volume":"316","author":"BF Arnold","year":"2016","unstructured":"Arnold, B. F. & Ercumen, A. Negative control outcomes: A tool to detect bias in randomized trials. JAMA 316, 2597\u20132598. https:\/\/doi.org\/10.1001\/jama.2016.17700 (2016).","journal-title":"JAMA"},{"key":"68037_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jbi.2016.12.005","volume":"66","author":"EA Voss","year":"2017","unstructured":"Voss, E. A. et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J. Biomed. Inform. 66, 72\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2016.12.005 (2017).","journal-title":"J. Biomed. Inform."},{"key":"68037_CR25","doi-asserted-by":"crossref","unstructured":"Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D. & Suchard, M. A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences 201708282, (2018).","DOI":"10.1073\/pnas.1708282114"},{"key":"68037_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1359\/jbmr.070904","volume":"23","author":"KE Ensrud","year":"2008","unstructured":"Ensrud, K. E. et al. Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial. J. Bone Miner. Res. 23, 112\u201320. https:\/\/doi.org\/10.1359\/jbmr.070904 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"68037_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMe0905480","volume":"361","author":"S Khosla","year":"2009","unstructured":"Khosla, S. Increasing options for the treatment of osteoporosis. N. Engl. J. Med. 361, 818\u201320. https:\/\/doi.org\/10.1056\/NEJMe0905480 (2009).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean, C. et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med. 148, 197\u2013213 (2008).","journal-title":"Ann. Intern. Med."},{"key":"68037_CR29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad, M. H. et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97, 1871\u201380. https:\/\/doi.org\/10.1210\/jc.2011-3060 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"68037_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001155.pub2","author":"GA Wells","year":"2008","unstructured":"Wells, G. A. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Datab. Syst. Rev.\nhttps:\/\/doi.org\/10.1002\/14651858.CD001155.pub2 (2008).","journal-title":"Cochrane Datab. Syst. Rev."},{"key":"68037_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","volume":"11","author":"M Luckey","year":"2004","unstructured":"Luckey, M. et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 11, 405\u201315 (2004).","journal-title":"Menopause"},{"key":"68037_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","volume":"255","author":"PN Sambrook","year":"2004","unstructured":"Sambrook, P. N. et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of effect (efficacy of fosamax versus evista comparison trial) international. J. Intern. Med. 255, 503\u201311. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01317.x (2004).","journal-title":"J. Intern. Med."},{"key":"68037_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2013","unstructured":"Wysowski, D. K. & Greene, P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002\u20132012. Bone 57, 423\u20138. https:\/\/doi.org\/10.1016\/j.bone.2013.09.008 (2013).","journal-title":"Bone"},{"key":"68037_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/jbmr.288","volume":"26","author":"SY Kim","year":"2011","unstructured":"Kim, S. Y., Schneeweiss, S., Katz, J. N., Levin, R. & Solomon, D. H. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J. Bone. Miner. Res. 26, 993\u20131001. https:\/\/doi.org\/10.1002\/jbmr.288 (2011).","journal-title":"J. Bone. Miner. Res."},{"key":"68037_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas, L., Solomon, D. H. & Kim, S. C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J. Bone. Miner. Res. 28, 1729\u201337. https:\/\/doi.org\/10.1002\/jbmr.1893 (2013).","journal-title":"J. Bone. Miner. Res."},{"key":"68037_CR36","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher, J., Michaelsson, K. & Aspenberg, P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1010650 (2011).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR37","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25, 2267\u201394. https:\/\/doi.org\/10.1002\/jbmr.253 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"68037_CR38","first-page":"1282","volume":"91","author":"MF Abdelmalek","year":"1996","unstructured":"Abdelmalek, M. F. & Douglas, D. D. Alendronate-induced ulcerative esophagitis. Am. J. Gastroenterol. 91, 1282\u20133 (1996).","journal-title":"Am. J. Gastroenterol."},{"key":"68037_CR39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM199610033351412","volume":"335","author":"DO Castell","year":"1996","unstructured":"Castell, D. O. \u201cPill esophagitis\u201d\u2014The case of alendronate. N. Engl. J. Med. 335, 1058\u20131059. https:\/\/doi.org\/10.1056\/NEJM199610033351412 (1996).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC de Groen","year":"1996","unstructured":"de Groen, P. C. et al. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335, 1016\u201321. https:\/\/doi.org\/10.1056\/NEJM199610033351403 (1996).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJM199610033351416","volume":"335","author":"UI Liberman","year":"1996","unstructured":"Liberman, U. I. & Hirsch, L. J. Esophagitis and alendronate. N. Engl. J. Med. 335, 1069\u201370. https:\/\/doi.org\/10.1056\/NEJM199610033351416 (1996).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc0808738","volume":"360","author":"DK Wysowski","year":"2009","unstructured":"Wysowski, D. K. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med. 360, 89\u201390. https:\/\/doi.org\/10.1056\/NEJMc0808738 (2009).","journal-title":"N. Engl. J. Med."},{"key":"68037_CR43","doi-asserted-by":"publisher","first-page":"c4444","DOI":"10.1136\/bmj.c4444","volume":"341","author":"J Green","year":"2010","unstructured":"Green, J. et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case\u2013control analysis within a UK primary care cohort. BMJ 341, c4444. https:\/\/doi.org\/10.1136\/bmj.c4444 (2010).","journal-title":"BMJ"},{"key":"68037_CR44","doi-asserted-by":"publisher","first-page":"e0123080","DOI":"10.1371\/journal.pone.0123080","volume":"10","author":"LX Chen","year":"2015","unstructured":"Chen, L. X. et al. The carcinogenicity of alendronate in patients with osteoporosis: Evidence from cohort studies. PLoS One 10, e0123080. https:\/\/doi.org\/10.1371\/journal.pone.0123080 (2015).","journal-title":"PLoS One"},{"key":"68037_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.11005\/jbm.2015.22.2.77","volume":"22","author":"GH Seo","year":"2015","unstructured":"Seo, G. H. & Choi, H. J. Oral bisphosphonate and risk of esophageal cancer: A nationwide claim study. J Bone Metab 22, 77\u201381. https:\/\/doi.org\/10.11005\/jbm.2015.22.2.77 (2015).","journal-title":"J Bone Metab"},{"key":"68037_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00198-012-2158-8","volume":"24","author":"K Sun","year":"2013","unstructured":"Sun, K., Liu, J. M., Sun, H. X., Lu, N. & Ning, G. Bisphosphonate treatment and risk of esophageal cancer: A meta-analysis of observational studies. Osteoporos Int 24, 279\u201386. https:\/\/doi.org\/10.1007\/s00198-012-2158-8 (2013).","journal-title":"Osteoporos Int"},{"key":"68037_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/kwt010","volume":"178","author":"D Madigan","year":"2013","unstructured":"Madigan, D. et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol 178, 645\u201351. https:\/\/doi.org\/10.1093\/aje\/kwt010 (2013).","journal-title":"Am J Epidemiol"},{"key":"68037_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/pan.2019.11","volume":"27","author":"G King","year":"2019","unstructured":"King, G. & Nielsen, R. Why propensity scores should not be used for matching. Political Analysis 27, 435\u2013454 (2019).","journal-title":"Political Analysis"},{"key":"68037_CR49","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem, A., Forciea, M. A., McLean, R. M. & Denberg, T. D. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the american college of physicians. Ann Intern Med 166, 818\u2013839. https:\/\/doi.org\/10.7326\/M15-1361 (2017).","journal-title":"Ann Intern Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68037-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:40:39Z","timestamp":1670334039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68037"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68037-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"26 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11115"}}